FDA hearing, VA psychedelic bill claims, and Alabama's marijuana rescheduling objection shape September 2026 policy briefing
Summary
The briefing examines three institutional developments shaping psychedelic policy. At a September 14 FDA hearing, roughly 80 speakers addressed provider training, patient safety, access, data standards, and possible Risk Evaluation and Mitigation Strategies for future psychedelic therapies, while a federal panel asked no questions. Testimony divided between strict, trial-based safeguards and more accessible models informed by state programs and real-world treatment. The report also finds that an American Legion resolution endorsing Senate bill S.4220 describes stronger VA infrastructure than the bill actually guarantees: the legislation permits, but does not require, centers of excellence and does not fund trials or create patient access. Finally, Alabama withdrew its objection to federal medical marijuana rescheduling after four months, illustrating how state-specific objection procedures could delay adoption if psilocybin or MDMA are federally rescheduled after approval.